Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2019 06:55 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City

WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO...
January 16, 2019 06:55 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Announces Meeting Date with FDA

WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug...
November 13, 2018 16:05 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended...
November 13, 2018 06:55 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharma Announces Positive Results in Second PRK Study

Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the...
November 13, 2018 06:55 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study

WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel...
October 02, 2018 06:55 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care

WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
September 25, 2018 06:55 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules

WALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
September 24, 2018 06:55 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies

WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
September 04, 2018 08:31 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies

WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
September 04, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis

WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...

Next Page keyboard_arrow_right